

PROGRAMME
EUROPEAN CHARCOT FOUNDATION
SYMPOSIUM 2009

**A new Treatment Era in Multiple Sclerosis
Options, Challenges, Risks**

November 12, 13 and 14, 2009

Lisbon, Portugal

15th European Charcot Foundation Lecture

Prof. M. Clanet

Thursday November 12, 2009

Trends in Treatment Strategies

European Charcot Foundation
Hoeveveld 18a, 6584 GG Molenhoek (Nijmegen area)
The Netherlands
Tel.: 31-24-3561954
Fax : 31-24-3540920
www.charcot-ms.eu

**“This European Charcot Foundation Symposium wants to prepare clinicians for a
new era of treatment”**

Thursday November 12, 2009

Chair: G. Ebers - O.R. Hommes

13.30	XV European Charcot Foundation Lecture Trends in Treatment Strategies	M. Clanet
14.30 – 15.00	Discussion	
	Session I Pathology, pathophysiology and clinical application of new concepts	
15.00	Pathophysiology of inflammation and tissue injury in MS: what are the targets for therapy?	H. Lassmann
15.20	New strategies in pathophysiology: on T-cell traffic and BBB	G. Comi
15.40	Clinical application of new concepts	G. Edan
16.00 – 16.30	Discussion	
16.30 – 17.00	Coffee break	
17.30 – 19.00	Integrated Satellite Symposium Novartis S1P receptor modulation: from target to treatment	
	Chair: G. Giovannoni	
17.30	Introduction and Welcome	G. Giovannoni
17.35	Targeting sphingosine receptors in the immune system and the CNS	J. Antel
18.00	Visualising treatment effects in MS	P. Vermersch
18.20	Oral fingolimod: the clinical data	E. Havrdova
18.40	Panel discussion	
18.55	Summary and conclusions	
19.00	Closure	
20.00 – 21.00	Welcome Reception	

Friday November 13, 2009

Chair: M. Freedman - J. Palace

Session II

Options, challenges and risks of new drugs

08.30	What to do in the Clinical Isolated Syndrome?	L. Kappos
08.50	What to do in fulminant Multiple Sclerosis?	P. Vermersch
09.10	The role of new drugs in the treatment of Relapsing Remitting Multiple Sclerosis	H.-P. Hartung
09.30	The role of new treatments in the progressive forms of Multiple Sclerosis: SPMS and PPMS	X. Montalban
09.50 – 10.10	Discussion	
10.10 – 10.45	Coffee break	

**11.00 – 12.30 Integrated Satellite Symposium Teva
Laquinimod: A novel oral immunomodulator in development for the treatment of MS**

Chair: X. Montalban

11.00	Introduction and welcome	X. Montalban
11.05	Insights into Laquinimod mechanisms of action	W. Brück
11.25	Efficacy and safety of Laquinimod: Current data and future perspectives	G. Comi
11.45	Making the right treatment decision. Importance of evaluating the risk-benefit ratio of MS treatment in the new era	B. Kieseier
12.05	Panel discussion	X. Montalban & G. Comi
12.25	Summary and conclusions	X. Montalban
12.30	Closure	
12.30 – 14.00	Lunch	

Chair: G. Comi - L. Kappos

Session III

**Response measurement and how to use the tools.
MRI, CSF, Biomarkers, Pharmacogenomics.**

14.00	How to evaluate the treatment response?	M. Freedman
14.20	The use of MRI in treatment response studies. Markers for inflammation, neuroprotection and repair	F. Barkhof
14.40	CSF and other Biomarkers. How to use them?	G. Giovannoni
15.00	Genome-wide association studies: susceptibility, clinical course and response to treatment	A. Compston
15.20	Arguments for ending treatment - when and how?	K. Selmaj
15.40 – 16.00	Discussion	
16.00 – 16.30	Coffee break	
20.00	Speakers' Dinner	

Saturday November 14, 2009

Chair: M. Clanet - G. Edan

Session IV

Atypical syndromes

09.00	On humoral immunological aspects in the brain of MS patients	E. Meinl
09.20	Neuromyelitis optica (NMO) and astrocytic damage in its pathogenesis	K. Fujihara
09.40	Sussac Syndrome, its diagnosis and treatment	X. Montalban
10.00 – 10.30	Coffee break	
10.30	Acute inflammatory white matter disorders	J. Palace
10.50	Auto-antibodies to CNS proteins in children with first demyelinating event – implications for diagnosis and prognosis	B. Hemmer
11.10 – 11.30	Discussion	
12.00 – 13.30	Lunch	

Chair: H.-P. Hartung - X. Montalban

Session V

The future

13.30	Are there emerging treatments that promise to reduce progression of the disease?	J. Wolinsky
13.50	Patient autonomy in treatment choices	C. Heesen
14.10 – 14.30	Discussion	
14.30 – 15.00	European Charcot Foundation Young Investigators Awards	
15.00	Closure	